HSP90AA1 and cancer: Hsp90 inhibitors were among the first Hsp inhibitors to be evaluated for use in anti-cancer treatment, and as these first-generation inhibitors were not satisfactory, second-generation compounds were developed, some of which have been selected for clinical trials.